



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

26 Jan 2015

[\[Click on blue hyperlink for further information\]](#)

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov).

Please be advised that you **must contact the Research Grants Management Office (RGMO) at least 60 days before the submission date**, Mr Eugene Baugaard ([eugeneb@sun.ac.za](mailto:eugeneb@sun.ac.za)), or as soon as you commit to apply for an NIH grant and that the grant is submitted institutionally.

## Important notices

- **Reminders Related to the NIH/AHRQ Policy for Application Submission** ([NOT-OD-15-059](#)) . The purpose of this Notice is to remind applicants that the basic requirements for allowable applications have not changed with the updated NIH/AHRQ policy on application submission. Investigators now may submit a New Application, following an unsuccessful application, without concern for scientific overlap with previously reviewed applications.
- **Findings of Research Misconduct** ([NOT-OD-15-060](#))
- **Salary Limitation on FY 2015 Agency for Healthcare Research and Quality (AHRQ) Grants, Cooperative Agreements, and Contracts.** ([NOT-HS-15-003](#)). This Notice provides information to applicants, grantees, and contractors of the Agency for Healthcare Research and Quality (AHRQ) regarding the salary cap limitations imposed for Fiscal Year 2015. The Consolidated and Further Continuing Appropriations Act, 2015, Public Law 113-235, signed into law on December 16, 2014, restricts the amount of direct salary which may be paid to an individual under an HHS grant, cooperative agreement, or applicable contract to a rate no greater than Executive Level II of the Federal Executive Pay Scale. Effective January 11, 2015, the Executive Level II salary level is \$183,300

### 1. Title: Prevention Research in Mid-Life Adults

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** [\(PA-15-097\)](#)  
[\(PA-15-098\)](#)

**Type:** R21  
R01

**Application Due Date:** Standard dates apply. For R21: 16 Feb, 16 Jun and 16 Oct 2015. For R01: 5 Feb, 5 Jun and 5 Oct 2015 by 5:00 PM local time of applicant organization.

**Purpose:** This Funding Opportunity Announcement (FOA) seeks to stimulate research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years.

**Budget:** R21 - The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 in direct costs may be requested in any single year. R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

### 2. Title: Reductions in Illicit Drug Use and Functional Outcomes

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** [\(PA-15-099\)](#)

**Type:** R21/R33

**Application Due Date:** Standard dates apply. 16 Feb, 16 Jun and 16 Oct 2015 by 5:00 PM local time of applicant organization. **Standard aids dates apply for aids applications:** 7 May, 7 Sept and 7 Jan.

**Purpose:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications for Phased Innovation (R21/R33) projects to determine whether reductions in illicit drug use are associated with positive changes in health-related and other functional outcomes in individuals with substance use disorders (SUDs). Functional outcomes include, for example, reductions in morbidity, mortality, criminal justice involvement, overall healthcare expenditures. This FOA provides support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by possible transition to expanded research support (R33 phase). The transition to the R33 phase will be determined by NIH program evaluation of successful achievement of the milestones set for the R21 phase. The ultimate goal of this FOA is to provide evidence that will enable regulatory authorities to accept reductions in illicit drug use as a valid outcome measure in clinical trials of pharmacotherapies for the treatment of SUDs.

**Budget:** For the R21 phase, the combined budget for direct costs during the two-year project period may not exceed \$275,000, with no more than \$200,000 requested in any single year. For the R33 phase, the direct costs should not exceed \$500,000 per year. 2 years for the R21 and up to 3 years for the R33.



**Brief definitions of some NIH grant mechanisms:** [comprehensive list of extramural grant and cooperative agreement activity codes](#)

**U01 – NIH Research Project Cooperative Agreement:** supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

**R01 – NIH Research Project Grant Program:** most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

**R03 – NIH Small Grant Program:** limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

**UH2/UH3 - Phase Innovation Awards Cooperative Agreement:** Exploratory/Developmental Cooperative Agreement Phase I and II. To support the development of new research activities in categorical program areas (Support generally is restricted in level of support and in time.) The UH3 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the UH2 mechanism. Although only UH2 awardees are generally eligible to apply for UH3 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under UH2.

**R21 – NIH Exploratory/Developmental Research Grant:** encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

**R21/R33 - Phased Innovation:** The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

Complete [Glossary and acronym list of NIH Terms](#)

**Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University**  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus. • Enquiries: *Dr Christa de Vries* • Tel: 9838 • Email: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)